Patents by Inventor Zhaoyin Wang

Zhaoyin Wang has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210047290
    Abstract: Disclosed in the present invention are an indoleamine-2,3-dioxygenase inhibitor and a preparation method therefor. The inhibitor of the present invention has a structure as represented by general formula (I), wherein the definitions of Ar, E, Y, X, V, D, W, B, ring A and ring B are as shown in the description and claims. Also disclosed in the present invention is a preparation method for the inhibitor. The compound of general formula (I) of the present invention can be used as an indoleamine-2,3-dioxygenase inhibitor for preparing a medicament for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.
    Type: Application
    Filed: February 12, 2019
    Publication date: February 18, 2021
    Inventors: Zhaoyin WANG, Wei GUO, Yongshuai CHAI
  • Publication number: 20200365897
    Abstract: A lithium-sulfur battery includes: a substrate; a composite cathode disposed on the substrate; a solid-state electrolyte disposed on the composite cathode; and a lithium anode disposed on the solid-state electrolyte, such that the composite cathode comprises: active elemental sulfur, conductive carbon, sulfide electrolyte, and ionic liquid.
    Type: Application
    Filed: May 18, 2020
    Publication date: November 19, 2020
    Inventors: Michael Edward Badding, Jun Jin, Zhen Song, Qing Wang, Zhaoyin Wen, Tongping Xiu
  • Publication number: 20200352906
    Abstract: The use of EP4 receptor antagonist compounds represented by Formula (I) (or pharmaceutically acceptable salts thereof) as defined herein is provided for treating cancer or inflammatory disease by administering such an EP4 antagonist alone or in combination with an antibody therapy, radiation therapy, anti-metabolite chemotherapy to a subject in need thereof.
    Type: Application
    Filed: February 2, 2019
    Publication date: November 12, 2020
    Applicants: Shenzhen Ionova Life Science Co., Ltd., Foshan Ionova Biotherapeutics Co., Inc.
    Inventors: Gang Zhou, Yongkui Sun, Zhaoyin Wang
  • Publication number: 20200325161
    Abstract: Heterocyclic compounds are provided as arginase inhibitors, in particular to a compound represented by Formula (I), or a pharmaceutically acceptable salt, stereoisomer or tautomer, or prodrug thereof and a pharmaceutical composition including the compound.
    Type: Application
    Filed: December 21, 2018
    Publication date: October 15, 2020
    Applicant: Guangdong Newopp Biopharmaceuticals Co., Ltd.
    Inventors: Zhaoyin Wang, Nanxin Li, Jianbin Ma, Yanqiang Shao
  • Publication number: 20200253978
    Abstract: This disclosure relates to heterocyclics as selective inhibitors of the fibroblast growth factor receptor 4 (FGFR-4), in particular relates to a compound of Formula I or a pharmaceutically acceptable salt thereof, and a pharmaceutical composition including the compound.
    Type: Application
    Filed: April 24, 2020
    Publication date: August 13, 2020
    Applicant: ADVNET PHARMA CO. LTD.
    Inventors: Zhaoyin Wang, Nanxin Li
  • Publication number: 20200246295
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Application
    Filed: April 21, 2020
    Publication date: August 6, 2020
    Inventors: Yongshuai CHAI, Sven Erik GODTFREDSEN, Mark KAGAN, Yugang LIU, Mahavir PRASHAD, Zhaoyin WANG, Saijie ZHU
  • Patent number: 10668035
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Grant
    Filed: April 18, 2019
    Date of Patent: June 2, 2020
    Assignee: Novartis AG
    Inventors: Yongshuai Chai, Sven Erik Godtfredsen, Mark Kagan, Yugang Liu, Mahavir Prashad, Zhaoyin Wang, Saijie Zhu
  • Publication number: 20190240177
    Abstract: The present disclosure provides a compound of Formula (I); or a pharmaceutically acceptable salt thereof, wherein R1 and R2 are defined herein. The disclosure also relates to a method for manufacturing the compounds of the disclosure, and its therapeutic uses. The present disclosure further provides pharmaceutical composition of the compounds of the disclosure and a combination of pharmacologically active agents and a compound of the disclosure.
    Type: Application
    Filed: April 18, 2019
    Publication date: August 8, 2019
    Inventors: Yongshuai CHAI, Sven Erik GODTFREDSEN, Mark KAGAN, Yugang LIU, Mahavir PRASHAD, Zhaoyin WANG, Saijie ZHU
  • Publication number: 20190152932
    Abstract: Disclosed are a compound represented by general formula I and a preparation method therefor. The compound can be used as indoleamine-2,3-dioxygenase inhibitor to prepare medicines for preventing and/or treating indoleamine-2,3-dioxygenase-mediated diseases.
    Type: Application
    Filed: September 15, 2015
    Publication date: May 23, 2019
    Inventors: Zhaoyin WANG, Wei GUO, Jidong ZHU
  • Patent number: 9458162
    Abstract: The present document describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using such compounds. More specifically, the present document describes compound of Formula (A): (Formula (A)) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods of synthesizing and using such compounds.
    Type: Grant
    Filed: January 30, 2013
    Date of Patent: October 4, 2016
    Assignee: Nanjing Allgen Pharma Co. Ltd.
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Patent number: 9345905
    Abstract: The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.
    Type: Grant
    Filed: November 29, 2012
    Date of Patent: May 24, 2016
    Assignee: NANJING ALLGEN PHARMA CO. LTD.
    Inventors: Zhaoyin Wang, Lianhai Li
  • Patent number: 9226923
    Abstract: The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fluorophenyl)ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers.
    Type: Grant
    Filed: July 26, 2012
    Date of Patent: January 5, 2016
    Assignee: Nanjing Allgen Pharma Co. Ltd.
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Patent number: 8946445
    Abstract: The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.
    Type: Grant
    Filed: October 11, 2012
    Date of Patent: February 3, 2015
    Assignee: Nanjing Allgen Pharma Co., Ltd.
    Inventor: Zhaoyin Wang
  • Patent number: 8937088
    Abstract: A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit.
    Type: Grant
    Filed: January 5, 2012
    Date of Patent: January 20, 2015
    Assignees: Astar Biotech LLC, Beta Pharma Canada Inc.
    Inventors: Zhaoyin Wang, Chunrong Yu
  • Publication number: 20150011530
    Abstract: The present document describes novel molecules having protein tyrosine kinase inhibitory activity, and methods of synthesizing and using such compounds. More specifically, the present document describes compound of Formula (A): (Formula (A)) or a pharmaceutically acceptable salt, hydrate or solvate thereof, and methods of synthesizing and using such compounds.
    Type: Application
    Filed: January 30, 2013
    Publication date: January 8, 2015
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Publication number: 20140322229
    Abstract: The present document describes compounds of Formula I, pharmaceutical compositions comprising the same as well as methods of treating diseases such as a cancer, neurological disease, neurodegenerative disorder, stroke, traumatic brain injury, parasitic infection, inflammation or an autoimmune disease with said compounds.
    Type: Application
    Filed: November 29, 2012
    Publication date: October 30, 2014
    Inventors: Zhaoyin Wang, Lianhai Li
  • Publication number: 20140256768
    Abstract: The present document describes novel compounds which may inhibit the activity of anti-apoptotic proteins such as Bcl-2 family protein members, compositions containing the compounds and methods of treating diseases involving a defect in apoptosis, such as, for example, in the treatment of cancer.
    Type: Application
    Filed: October 11, 2012
    Publication date: September 11, 2014
    Inventor: Zhaoyin Wang
  • Publication number: 20140243303
    Abstract: The present invention relates to spirocyclic compounds of formula I, namely spirocyclic (1H-pyrazol-4-yl)-3-(1-(2,6-dichloro-3-fiuorophenyl)ethoxy)pyridin-2-amines having protein kinase inhibitory activity, and methods of synthesizing and using such compounds. Preferred compounds are c-Met and/or ALK inhibitors useful for the treatment of abnormal cell growth, such as cancers.
    Type: Application
    Filed: July 26, 2012
    Publication date: August 28, 2014
    Applicant: Beta Pharma Canada Inc.
    Inventors: Zhaoyin Wang, Lianhai Li, Zhigang Wang
  • Patent number: 8637541
    Abstract: The compound (+) {7R-[[(4-fluorophenyl)sulfonyl] (methyl)ammo]-6,7,8,9-tetrahydropyrido[1,2-a]mdol-10-yl}acetic acid and pharmaceutically acceptable salts thereof are antagonists of the PGD2 receptor, CRTH2, and as such are useful in the treatment and/or prevention of CRTH2-meidated diseases such as asthma.
    Type: Grant
    Filed: September 17, 2009
    Date of Patent: January 28, 2014
    Assignee: Merck Canada Inc.
    Inventor: Zhaoyin Wang
  • Publication number: 20130296380
    Abstract: A compound of Formula (I), salts thereof, prodrugs thereof, metabolites thereof, pharmaceutical compositions containing such a compound, and use of such compound and compositions to treat diseases mediated by multiple kinases, such as raf, VEGFR, PDGFR, FLT-3, and c-Kit.
    Type: Application
    Filed: January 5, 2012
    Publication date: November 7, 2013
    Applicant: Beta Pharma Canada Inc.
    Inventors: Zhaoyin Wang, Chunrong Yu